2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 22 222 | - | - | ||
| 3 719 | - | - | ||
| 7 720 | - | - | ||
| 11 412 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenWhat do you think will happen on Monday?
·6 t sittenIn the coming weeks, a lot can happen. I am increasing my exposure as much as I can, and here is the reason: CIRCIO IS A RARE CASE. There are many small biotech companies listed on the stock exchange. But there are few listed companies with a platform that can potentially impact several large areas within gene and cell therapy. That is why Circio stands out. circVec is not just about one indication. The technology attempts to solve fundamental problems in the field: too low efficacy, too high doses, too short duration, and too much toxicity. AAV. LNP. In vivo cell therapy. Heart. Eye. CNS. Several on the forum have noticed that such platform cases are usually private at this stage. They are often owned by venture funds, larger industrial players, or specialized biotech investors before ordinary shareholders get the opportunity to participate. Circio is an exception. The risk is high. This is still preclinical biotech, and nothing is guaranteed. But the asymmetry is unusual. We are now in the latter part of Q2, and the company has pointed to several important milestones in AAV and T-cell delivery. June can therefore be an important month. Circio is not a usual small-cap stock. It is an extremely rare listed entry into a platform case in a field where the most interesting companies are often bought before most people get the chance. I don't think I will ever get such an opportunity again. Therefore, I am buying more and holding on. Not because the risk is low. But because I believe the potential upside is extraordinary if circVec continues to deliver.
·1 t sittenVery much agree with Modernity, thinking along the same lines. Therefore, I will subscribe for many more warrants than what was planned for the webcast. This will most likely be the last time they raise money, so I would gladly contribute to them reaching the goal of 300 MNOK! Have a good weekend.
·7 t sittenWhat do people expect to happen in the coming weeks!?🙌🏼
·7 t sittenThe purchase of the subscription rights stops on June 3rd, some news will come on June 5th to increase the exchange of TR and the price goes up a couple of kroner.
·3 t sitten · Muokattua bit boring answer but the rights will probably hold back the price for a while, it will get a little better after June 3 and even a little more after June 9 when the holiday is over then this is probably ready for climbing, news can cause fluctuations and change the natural a bit. 10.8 was the issue price in the last issue, this should come not too long from now.
·9 t sittenDoes anyone have a good outline for a potential licensing agreement (or agreements) and what it would provide to the company, and how it would be used within the company?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenWhat do you think will happen on Monday?
- ·6 t sittenIn the coming weeks, a lot can happen. I am increasing my exposure as much as I can, and here is the reason: CIRCIO IS A RARE CASE. There are many small biotech companies listed on the stock exchange. But there are few listed companies with a platform that can potentially impact several large areas within gene and cell therapy. That is why Circio stands out. circVec is not just about one indication. The technology attempts to solve fundamental problems in the field: too low efficacy, too high doses, too short duration, and too much toxicity. AAV. LNP. In vivo cell therapy. Heart. Eye. CNS. Several on the forum have noticed that such platform cases are usually private at this stage. They are often owned by venture funds, larger industrial players, or specialized biotech investors before ordinary shareholders get the opportunity to participate. Circio is an exception. The risk is high. This is still preclinical biotech, and nothing is guaranteed. But the asymmetry is unusual. We are now in the latter part of Q2, and the company has pointed to several important milestones in AAV and T-cell delivery. June can therefore be an important month. Circio is not a usual small-cap stock. It is an extremely rare listed entry into a platform case in a field where the most interesting companies are often bought before most people get the chance. I don't think I will ever get such an opportunity again. Therefore, I am buying more and holding on. Not because the risk is low. But because I believe the potential upside is extraordinary if circVec continues to deliver.·1 t sittenVery much agree with Modernity, thinking along the same lines. Therefore, I will subscribe for many more warrants than what was planned for the webcast. This will most likely be the last time they raise money, so I would gladly contribute to them reaching the goal of 300 MNOK! Have a good weekend.
- ·7 t sittenWhat do people expect to happen in the coming weeks!?🙌🏼·7 t sittenThe purchase of the subscription rights stops on June 3rd, some news will come on June 5th to increase the exchange of TR and the price goes up a couple of kroner.·3 t sitten · Muokattua bit boring answer but the rights will probably hold back the price for a while, it will get a little better after June 3 and even a little more after June 9 when the holiday is over then this is probably ready for climbing, news can cause fluctuations and change the natural a bit. 10.8 was the issue price in the last issue, this should come not too long from now.
- ·9 t sittenDoes anyone have a good outline for a potential licensing agreement (or agreements) and what it would provide to the company, and how it would be used within the company?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 22 222 | - | - | ||
| 3 719 | - | - | ||
| 7 720 | - | - | ||
| 11 412 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenWhat do you think will happen on Monday?
- ·6 t sittenIn the coming weeks, a lot can happen. I am increasing my exposure as much as I can, and here is the reason: CIRCIO IS A RARE CASE. There are many small biotech companies listed on the stock exchange. But there are few listed companies with a platform that can potentially impact several large areas within gene and cell therapy. That is why Circio stands out. circVec is not just about one indication. The technology attempts to solve fundamental problems in the field: too low efficacy, too high doses, too short duration, and too much toxicity. AAV. LNP. In vivo cell therapy. Heart. Eye. CNS. Several on the forum have noticed that such platform cases are usually private at this stage. They are often owned by venture funds, larger industrial players, or specialized biotech investors before ordinary shareholders get the opportunity to participate. Circio is an exception. The risk is high. This is still preclinical biotech, and nothing is guaranteed. But the asymmetry is unusual. We are now in the latter part of Q2, and the company has pointed to several important milestones in AAV and T-cell delivery. June can therefore be an important month. Circio is not a usual small-cap stock. It is an extremely rare listed entry into a platform case in a field where the most interesting companies are often bought before most people get the chance. I don't think I will ever get such an opportunity again. Therefore, I am buying more and holding on. Not because the risk is low. But because I believe the potential upside is extraordinary if circVec continues to deliver.·1 t sittenVery much agree with Modernity, thinking along the same lines. Therefore, I will subscribe for many more warrants than what was planned for the webcast. This will most likely be the last time they raise money, so I would gladly contribute to them reaching the goal of 300 MNOK! Have a good weekend.
- ·7 t sittenWhat do people expect to happen in the coming weeks!?🙌🏼·7 t sittenThe purchase of the subscription rights stops on June 3rd, some news will come on June 5th to increase the exchange of TR and the price goes up a couple of kroner.·3 t sitten · Muokattua bit boring answer but the rights will probably hold back the price for a while, it will get a little better after June 3 and even a little more after June 9 when the holiday is over then this is probably ready for climbing, news can cause fluctuations and change the natural a bit. 10.8 was the issue price in the last issue, this should come not too long from now.
- ·9 t sittenDoes anyone have a good outline for a potential licensing agreement (or agreements) and what it would provide to the company, and how it would be used within the company?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 22 222 | - | - | ||
| 3 719 | - | - | ||
| 7 720 | - | - | ||
| 11 412 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt